Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...

OXB and Bristol Myers Squibb (BMS) are expanding a partnership regarding manufacture and supply of lentiviral vectors for BMS’ CAR-T programs.

DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic ...

Seasoned oncology drug development leader joins following early clinical proof-of-concept for WEE1 inhibitor, APR-1051DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.

OXB to become commercial manufacturer of lentiviral vectors for Bristol Myers Squibb (BMS) CAR-T programmesMulti-year agreement with five-year ...

Curcumin and milk thistle extracts reduce oxidative stress, enhance vaccine response and support intestinal integrity in ...

Google DeepMind’s research team recently published in the international academic journal *Nature* the development process of ...

An international research team with strong participation from DTU has developed a new biotechnological platform that makes it ...

Five-year data from the KEYNOTE–942 trial show that the personalized mRNA cancer vaccine intismeran autogene, combined with ...